Mechanism Based Resistance to Aspirin

NCT ID: NCT00948987

Last Updated: 2009-10-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 400 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-09-30
• Study Completion Date: 2009-10-31

Brief Summary

The purpose of this research is to study why some people do not respond to the benefits of aspirin therapy. The benefit of aspirin is cardioprotection, or decreasing the risk of heart attack and/or stroke. Aspirin works by disabling the platelets, part of the blood cells used in clotting, from sticking together and forming blood clots, thus protecting the heart. It has been observed that failure to respond to aspirin therapy occurs in about 10% of the general population and that despite taking aspirin everyday, this group of non- responders is not getting protection for their heart. The investigators would like to determine why and how this happens.

Conditions

Aspirin Resistance; Pharmacological Aspirin Non-responsiveness

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Aspirin

single dose of aspirin 325 mg p.o.

Group Type: EXPERIMENTAL

Aspirin

Intervention Type: DRUG

325 mg enteric coated single dose p.o.

Interventions

Aspirin

325 mg enteric coated single dose p.o.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Age between 18 - 55
• Subjects must be in good health as based on medical history, physical examination, vital signs, and laboratory tests.
• All subjects must be non- smoking volunteers
• Female subjects of child bearing potential must be using a medically acceptable method of contraception (oral contraception, depo-provera injection, IUD, condom with spermicide, diaphragm, cervical cap, progestin implant, abstinence, tubal ligation, oophorectomy, TAH) throughout the entire study period. All female subjects must consent to a urine pregnancy test at screening and just prior to the start of each treatment phase of the study, which must be negative at all time points.
• Subjects must be within 30% of their ideal body weight.

Exclusion Criteria

• Female subjects who are pregnant or nursing a child.
• Subjects, who have received an experimental drug, used an experimental medical device within 30 days prior to screening, or who gave a blood donation of ≥ one pint within 8 weeks prior to screening.
• Subjects with any coagulation, bleeding or blood disorders.
• Subjects who are sensitive or allergic to aspirin as well as any of their components.
• Subjects with documented history of any gastrointestinal disorders, including bleeding ulcers.
• Subjects with any evidence of cancer.
• Subjects with a history of heart disease, including myocardial infarction, angina, coronary artery disease, any evidence of coronary artery stenosis, arrhythmias, heart failure, having had a CABG
• Subjects with renal, hepatic, respiratory, endocrine, metabolic, hematopoietic or neurological disorder.
• Subjects with any abnormal laboratory value or physical finding that according to the investigator may interfere with interpretation of the study results, be indicative of an underlying disease state, or compromise the safety of a potential subject.
• Subjects who have had a history of drug or alcohol abuse within the last 6 months.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

Bayer

INDUSTRY

Sponsor Role: collaborator

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

University of Pennsylvania

Principal Investigators

Garret A FitzGerald, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania, Institute for Translationals Medicine and Therapeutics

Susanne Fries, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania, Institute for Translationals Medicine and Therapeutics

Tilo Grosser, MD

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania, Institute for Translationals Medicine and Therapeutics

References

Grosser T, Fries S, Lawson JA, Kapoor SC, Grant GR, FitzGerald GA. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation. 2013 Jan 22;127(3):377-85. doi: 10.1161/CIRCULATIONAHA.112.117283. Epub 2012 Dec 4.

Reference Type: DERIVED

PMID: 23212718 (View on PubMed)

Other Identifiers

0926

Identifier Type: -

Identifier Source: secondary_id

801907

Identifier Type: -

Identifier Source: org_study_id